Exendin-4, a glucagon-like peptide-1 (GLP-1) receptor agonist is among those treatments of type 2 diabetes that lower blood glucose level by increasing glucose-dependent insulin secretion and suppressing excess glucagon secretion [85]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.